Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SCN4A | P35499 | 6/20 | 0.54 |
| ▸ | SIGMAR1 | Q99720 | 4/20 | 0.51 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.46 |
| ▸ | MAOB | P27338 | 4/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | PPARG | P37231 | 1/20 | 0.41 |
| ▸ | PPARA | Q07869 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5663771 | 0.82 | SIGMAR1 (0.53) | SCN4ASIGMAR1CYP1A2MAOBKMT2A | |
| SCHEMBL16790621 | 0.82 | SCN4A (0.55) | SCN4ACYP1A2KMT2ASMN1; SMN2 | |
| SCHEMBL5661525 | 0.82 | SIGMAR1 (0.53) | SCN4ASIGMAR1CYP1A2MAOBKMT2A | |
| SCHEMBL8607930 | 0.80 | SCN4A (0.58) | SCN4ASIGMAR1CYP1A2 | |
| SCHEMBL10925634 | 0.80 | LMNA (0.59) | SCN4A | |
| SCHEMBL2312172 | 0.79 | SCN4A (0.52) | SCN4ASIGMAR1CYP1A2MAOBKMT2A | |
| SCHEMBL3441819 | 0.78 | SCN4A (0.61) | SCN4ASIGMAR1CYP1A2MAOBPPARG | |
| SCHEMBL12461736 | 0.78 | MMP2 (0.49) | SCN4AMAOB | |
| SCHEMBL6453813 | 0.77 | PPARG (0.47) | SCN4ASIGMAR1CYP1A2KMT2APPARG | |
| SCHEMBL773201 | 0.77 | CYP1A2 (0.63) | SCN4ACYP1A2KMT2ASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030212273-A1 | Pyrrolo [2,3-D] pyrimidine compounds | PFIZER INC. | 2003-11-13 | — | — | US | disclosed |
| US-20020019526-A1 | Pyrrolo[2,3-d]pyrimidine compounds | PFIZER INC. | 2002-02-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020019526-A1 | Pyrrolo[2,3-d]pyrimidine compounds | JAK1, JAK3, JAK2 | SCN4A 4676/4885SIGMAR1 4528/4885CYP1A2 1601/4885 |
| US-20030212273-A1 | Pyrrolo [2,3-D] pyrimidine compounds | JAK1, JAK3, JAK2 | SCN4A 4676/4885SIGMAR1 4528/4885CYP1A2 1601/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.